Elevance Health (NYSE:ELV) Issues FY 2025 Earnings Guidance

Elevance Health (NYSE:ELV - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 30.000-30.000 for the period, compared to the consensus EPS estimate of 29.920. The company issued revenue guidance of -.

Analyst Ratings Changes

Several research firms have recently commented on ELV. Leerink Partners reissued a "market perform" rating and issued a $310.00 price objective (down previously from $510.00) on shares of Elevance Health in a report on Friday, July 18th. Wells Fargo & Company decreased their target price on Elevance Health from $412.00 to $403.00 and set an "overweight" rating on the stock in a research report on Wednesday. Leerink Partnrs lowered Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. dropped their price target on Elevance Health from $472.00 to $384.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 22nd. Finally, UBS Group decreased their price target on Elevance Health from $435.00 to $425.00 and set a "buy" rating for the company in a report on Friday, September 5th. Twelve investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $397.89.

Elevance Health Stock Up 0.3%

ELV stock opened at $346.36 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.44 and a current ratio of 1.56. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The company has a market cap of $76.97 billion, a price-to-earnings ratio of 14.16, a P/E/G ratio of 1.26 and a beta of 0.59. The business's 50-day moving average is $326.42 and its two-hundred day moving average is $353.99.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.03 by $1.00. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm had revenue of $50.09 billion during the quarter, compared to analysts' expectations of $49.26 billion. During the same quarter last year, the business posted $8.37 earnings per share. The firm's revenue was up 12.0% on a year-over-year basis. As a group, analysts forecast that Elevance Health will post 33.96 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 19th. Shareholders of record on Friday, December 5th will be issued a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 2.0%. The ex-dividend date is Friday, December 5th. Elevance Health's dividend payout ratio (DPR) is currently 29.11%.

Insiders Place Their Bets

In related news, Director Susan D. Devore bought 1,200 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was purchased at an average price of $312.15 per share, for a total transaction of $374,580.00. Following the acquisition, the director owned 3,502 shares in the company, valued at $1,093,149.30. This trade represents a 52.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.29% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Elevance Health

A number of institutional investors and hedge funds have recently modified their holdings of ELV. State of Wyoming purchased a new position in shares of Elevance Health in the 2nd quarter worth approximately $127,000. Transamerica Financial Advisors LLC lifted its stake in shares of Elevance Health by 43.9% during the 2nd quarter. Transamerica Financial Advisors LLC now owns 616 shares of the company's stock worth $239,000 after acquiring an additional 188 shares during the last quarter. MUFG Securities EMEA plc bought a new stake in shares of Elevance Health during the 2nd quarter worth approximately $260,000. Kestra Investment Management LLC lifted its holdings in shares of Elevance Health by 20.8% in the 2nd quarter. Kestra Investment Management LLC now owns 709 shares of the company's stock worth $276,000 after buying an additional 122 shares during the period. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of Elevance Health in the 2nd quarter worth $363,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.